TSTakashi Shirasaki

Takashi Shirasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takashi Shirasaki has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The role of periostin in eosinophilic otitis media

    by Hisanori Nishizawa, Atsushi Matsubara, Takashi Nakagawa, Nobuo Ohta, Kenji Izuhara, Takashi Shirasaki, Takahisa Abe, Ikuko Takeda, Hideichi Shinkawa

    We investigated the localization of periostin in middle ear specimens from patients with eosinophilic otitis media (EOM) and from a newly constructed animal model for EOM. Periostin-positive immunostaining was observed in the middle ear sections obtained from the EOM patients. Immunoreactivity for periostin was also seen in the animal model. These results suggest that periostin plays an important role in subepithelial fibrosis in the middle ear in EOM. The purpose of the present study was to investigate the role of periostin in the middle ear of EOM patients and an animal model. Histological and immunohistochemical analyses for periostin were carried out in the middle ear specimens of six EOM patients with/without asthma. An animal model of EOM was constructed by intraperitoneal and topical sensitization with ovalbumin (OVA). Histological and immunocytochemical analyses for periostin were also performed in this model. Immunoreactivities for periostin were observed in the basement membrane and extracellular matrix of the middle ear sections obtained from all EOM patients with/without asthma. In the animal model, eosinophil infiltration and middle ear mucosa thickness were observed. Moreover, periostin-positive immunostaining was shown in the extracellular matrix of the middle ear mucosa on the side topically boosted by OVA.


  • Open Access

    Differential expression of topoisomerase IIα protein in salivary gland carcinomas: histogenetic and prognostic implications

    by Shin-Ichiro Maruya, Takashi Shirasaki, Takahiko Nagaki, Seiji Kakehata, Hidekachi Kurotaki, Hiroki Mizukami, Hideichi Shinkawa

    Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis. Topoisomerase IIα (topoIIα), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication. The purpose of this study was to evaluate the expression of topoIIα in various types of salivary gland tumors and its biological significance.


    • 1 February 2009
      • Vol. 36  (2) , 237-40

    [Treatment results of chemotherapy with S-1 for head and neck cancer].

    by Takashi Shirasaki, Shin-Ichiro Maruya, Atsushi Namba, Atsushi Matsubara, Hideichi Shinkawa

    A study of chemotherapy treatment with S-1 in patients with head and neck cancer was conducted in 20 patients with residual tumor after primary chemoradiotherapy, or recurrent tumors. Treatment courses consisted of oral administration of S-1 at a dose of 80 to 120 mg/day depending on the body surface area for 14 consecutive day followed by a 7- day rest period. The response rate in patients with residual tumors after primary chemoradiotherapy was 55.6%(5/9). In patients with recurrent tumors, the response rate was 0%(0/11), however, median survival time was 534.5 days. Therefore, S-1 seemed to be useful for the treatment of patients with head and neck cancer from the point of QOL.

  • Open Access

    Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma

    by Takashi Shirasaki, Shin-Ichiro Maruya, Hiroki Mizukami, Seiji Kakehata, Hidekachi Kurotaki, Soroku Yagihashi, Hideichi Shinkawa

    Background: Thymidylate synthase (TS) is an important target for chemotherapeutic treatment of cancer and high expression of TS has been associated with poor prognosis or refractory disease in several cancers including colorectal and head and neck cancer. Although TS is known to regulate cell cycles and transcription factors, its potency as a therapeutic target has not been fully explored in adenoid cystic carcinoma (ACC).Methods: An ACC cell line (ACC3) was transfected with siRNA targeting the TS gene and inhibition of cell growth and induction of apoptosis-associated molecules were evaluatedin vitro. In addition, thein vivoeffect of TS siRNA on tumor progression was assessed using a xenograft model.Results: Our results demonstrated that ACC3 cells showed significantly higher TS expression than non-cancer cell lines and the induction of TS siRNA led to inhibition of cell proliferation. The effect was associated with an increase in p53, p21, and active caspase-3 and S-phase accumulation. We also found up-regulation of spermidine/spermine N1-acetyltransferase (SSAT), a polyamine metabolic enzyme. Furthermore, treatment with TS siRNA delivered by atelocollagen showed a significant cytostatic effect through the induction of apoptosis in a xenograft model.Conclusion: TS may be an important therapeutic target and siRNA targeting TS may be of potential therapeutic value in ACC.